Project Grant R21AI197006
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant of $890,877 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the La Jolla Institute for Immunology, effective February 1, 2026, through January 31, 2031. This award funds basic immunological research aimed at elucidating the structural and functional mechanisms of Interleukin-1 Receptor 8 (IL-1R8), a critical immunoregulatory protein that...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded La Jolla Institute for Immunology a Project Grant of $566,875 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period from February 18, 2026, through January 31, 2028. The grant supports research to deorphanize a novel G-protein coupled receptor (GPCR) expressed by tissue-resident memory T cells (TRM cells), with the ultimate objective of identifying its...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Feinstein Institutes For Medical Research a Project Grant of $460,625 under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective February 10, 2026, with a completion date of January 31, 2028. The award supports biomedical research focused on understanding the maturation and maintenance of the germinal center niche, specifically investigating follicular dendritic cells...
- Federal Grant Award Summary Yale University received a $462,052 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded February 19, 2026, with completion targeted for January 31, 2028. The research, conducted at Yale's New Haven, Connecticut facility, investigates the role of Erythroblast Transformation Specific 2 (ETS2), a transcription factor, in mediating monocyte activation...
- Federal Project Grant Award Summary Biotherapeutics, Inc. received a $314,363 Project Grant award from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025, through January 31, 2026. The award supports the development of a novel oral small molecule therapeutic candidate for treating systemic lupus erythematosus (SLE), an autoimmune disease affecting 1.5 million Americans. The company has...
- Federal Grant Award Summary The University of Oklahoma Health Sciences Center received a $1,049,245 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 4, 2025, with completion targeted for August 31, 2029. This grant supports biomedical research investigating the role of ARID3A (A+T-Rich Interaction Domain Protein 3A) in autoimmune B cell dysfunction associated with...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of California, San Diego a $3.19 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 16, 2025, with a completion date of June 30, 2029. This grant funds investigator-initiated biomedical research examining the roles and regulation of tissue-resident CD8 T cells during persistent viral infection, utilizing the lymphocytic...
- Federal Project Grant Summary Award Overview Loyola University of Chicago's Health Sciences Campus received a $423,500 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on June 25, 2025, with a completion date of May 31, 2027. The research initiative focuses on developing novel antibodies targeting autoreactive B cells as a potential therapeutic intervention for systemic lupus...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $489,500 to the Beckman Research Institute of the City of Hope under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 5, 2026, for a project period extending through January 31, 2028. The award supports fundamental research to elucidate the molecular mechanisms governing non-canonical microRNA-146a (mir-146a) biogenesis and its role in inflammatory...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $647,181 to the University of California, Merced under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 1, 2026, for a five-year project period concluding January 31, 2031. The project, titled "Elucidating Factors Involved in Inflammasome Regulation," focuses on fundamental research to advance understanding of inflammasome assembly and regulatory...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded La Jolla Institute for Immunology a Project Grant of $476,436 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period February 5, 2026 through January 31, 2028. The award supports research to define the function and regulation of ILRUN, a novel Systemic Lupus Erythematosus (SLE)-susceptibility gene identified through genome-wide association studies as significantly overexpressed in activated CD4+ T cells. The research deliverables comprise two primary aims: (1) identification of functional SLE-risk variants associated with ILRUN expression through CRISPRi assays, luciferase reporter assays, and chromatin immunoprecipitation (ChIP) assays to characterize enhancers, promoter variants, and transcription factor binding sites; and (2) functional characterization of ILRUN's role in CD4+ T cell biology, including assessment of its effects on cell activation, apoptosis, proliferation, differentiation, and cytokine production. The research products will provide mechanistic insights into the genetic basis of SLE and identify potential novel therapeutic targets for this serious autoimmune disease with limited treatment options.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $476.4k | 2/5/26 |